SR One, the corporate venturing unit of pharmaceutical company GlaxoSmithKline, has helped Auxogyn, a US-based women’s reproductive health company, raise $18m.
SR One led the series B round, and was joined by prior investors in Auxogyn, Merck Serono Ventures, the corporate venturing unit of the eponymous Germany-based pharmaceuticals group, as well as venture firms Kleiner Perkins Caufield and Byers and TPG Biotech.
Simeon J. George, partner at SR One, and Nilesh Kumar, director of Merck Serono Ventures, have joined Auxogyn’s board.
George said, "Auxogyn’s first product, Eeva, provides a predictive tool that will, for the first time in the IVF field, enable an objective, non-invasive assessment of embryo viability. We believe Eeva has the potential to improve infertility treatment and provide confidence to IVF clinicians and patients worldwide."
Auxogyn’s Early Embryo Viability Assessment (Eeva) Test helps intravenous fertilisation (IVF) by providing clinicians and patients with information allowing them to select embryos for transfer.
In February Merck Serono Ventures, TPG Biotech and Kleiner Perkins Caufield & Byers helped Auxogyn raise $20m.